Navigation Links
ULURU Inc. Reports Financial Results for Fourth Quarter and Year Ended December 31, 2010
Date:4/1/2011

$796,000 in revenues from the fourth quarter of 2009 compared to the fourth quarter of 2010 was primarily due to increased licensing fees due to the recognition of $751,000 in unamortized licensing fees from the termination of the licensing agreement with Meldex International.

For the year ended December 31, 2010, revenues were $1,557,000, compared to $668,000 for the same period of 2009.  The increase of approximately $889,000 was due primarily to the following factors: an increase of $903,000 in OraDisc™ licensing fees and an increase of $138,000 in Aphthasol® product sales as we did not sell any Aphthasol® finished product to our domestic distributor during 2009.  These increases were partially offset by decreases in Zindaclin® royalty and licensing fees of $87,000 due to our divestiture of this product in June 2010.

Research and Development

Research and development expenses for the fourth quarter of 2010 were $309,000, including $32,000 in share-based compensation, compared to $244,000, including $34,000 in share-based compensation, for the fourth quarter of 2009.  The increase of approximately $65,000 in research and development expenses was primarily due to higher costs of $50,000 associated with the development efforts for our Altrazeal® and OraDisc™ technologies.  

For the year ended December 2010, research and development expenses were $1.26 million, including $136,000 in share-based compensation, compared to $2.25 million, including $320,000 in share-based compensation, for the same period in 2009. The decrease of approximately $992,000 in research and development expenses was due primarily to decreases in direct research costs of $73,000, scientific personnel costs of $561,000, clinical testing expenses for our wound care technologies of $163,000, and regulatory consulting of $195,000.

Selling, general and administrative

Selling, general and admini
'/>"/>

SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2010 and to Provide a Business Update
2. ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®s Label Claim
3. ULURU Inc. Receives Letter of Non-Compliance From NYSE Amex
4. ULURU Inc. Announces Agreement With Exciton to Develop Antimicrobial Dressing
5. ULURU Inc. to Raise $500,000 in Registered Direct Offering
6. ULURU Inc. Reports Third Quarter 2010 Financial Results
7. ULURU Inc. Provides Altrazeal® Clinical Update
8. ULURU Inc. Announces Conference Call
9. ULURU Inc. Reports Second Quarter 2010 Financial Results
10. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
11. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015 Discovery Laboratories, Inc. (Nasdaq: ... on developing aerosolized KL4 surfactant therapies for respiratory ... at 8:30 a.m. Eastern Time on Tuesday August 11, ... 2015 second quarter financial results along with providing ... press release announcing the second quarter 2015 financial ...
(Date:8/3/2015)... -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), a ... of innovative therapies for the treatment of acute pain, ... for the three and six months ended June 30, ... July 23, 2015, the Committee for Medicinal Products for ... for the management of acute moderate-to-severe post-operative pain in ...
(Date:8/3/2015)... FLINT, Mich., Aug. 3, 2015 Diplomat Pharmacy, Inc. ... announced financial results for the quarter ended June 30, 2015. ... June 30, 2014. Second Quarter 2015 Highlights ... of 49% or $266 million , Total prescriptions dispensed ... of 8.6% versus 5.5% , Adjusted EBITDA of $22.7 ...
Breaking Medicine Technology:Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 3AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 4AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 5AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 6AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 7AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 8AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 9AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 2Diplomat Announces 2nd Quarter 2015 Financial Results 3Diplomat Announces 2nd Quarter 2015 Financial Results 4Diplomat Announces 2nd Quarter 2015 Financial Results 5Diplomat Announces 2nd Quarter 2015 Financial Results 6Diplomat Announces 2nd Quarter 2015 Financial Results 7Diplomat Announces 2nd Quarter 2015 Financial Results 8Diplomat Announces 2nd Quarter 2015 Financial Results 9Diplomat Announces 2nd Quarter 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 11Diplomat Announces 2nd Quarter 2015 Financial Results 12Diplomat Announces 2nd Quarter 2015 Financial Results 13Diplomat Announces 2nd Quarter 2015 Financial Results 14Diplomat Announces 2nd Quarter 2015 Financial Results 15Diplomat Announces 2nd Quarter 2015 Financial Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 17Diplomat Announces 2nd Quarter 2015 Financial Results 18
... 2010 Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) ... quarter ended September 30, 2010, on Tuesday, November 9, 2010 ... Company recently held an investor conference call on October 11th, ... with the release of the Company,s third quarter results.  The ...
... The Phase 3 results from the ADVANCE study ... The study reports an improvement in treatment discontinuation rates ... and demonstrates an increase in sustained viral response (SVR) ... endpoint for this study was SVR 24 weeks after ...
Cached Medicine Technology:Alexza Pharmaceuticals to Announce 2010 Third Quarter Financial Results on November 9, 2010 2Increased SVR and Decreased Adverse Events Reported in Final Results of Phase 3 Study on Telaprevir 2Increased SVR and Decreased Adverse Events Reported in Final Results of Phase 3 Study on Telaprevir 3
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... Members receiving ... quality care metrics – at a cost that is nine percent lower -- than ... Cross Blue Shield of New Jersey’s patient-centered programs. , “The promise of patient-centered, ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... and government entities, today announced that John Munro, a 15-year veteran of the ... of Managed Services Operations. , “I am thrilled to join Discovia at this ...
(Date:8/4/2015)... ... August 04, 2015 , ... Montclair State University and Atlantic Health ... of its kind in New Jersey, which starting this Fall will help prepare those ... School partnered with Atlantic Health System, one of the largest health care organizations in ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... Channel Report, finds the North America IT reseller channel will grow at least ... rates ahead of their 2014 pace and greater than their OEM/vendor partners. ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... Process Chemistry and Scale-up Online Seminar featuring researchers from Lubrizol, Pfizer, and ... at 1:00 PM EDT. , Process development project timelines often require informed decisions ...
Breaking Medicine News(10 mins):Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 2Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 3Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 3Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 2Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 3Health News:The 2112 Group Forecasts North America IT Channel to Grow At Least 6% in 2015 2Health News:The 2112 Group Forecasts North America IT Channel to Grow At Least 6% in 2015 3Health News:METTLER TOLEDO Announces New Process Chemistry and Scale-up Online Seminar 2
... INDIANAPOLIS, April 30 SynCare, LLC, today announced it ... assessments for HealthCare USA members in Missouri. HealthCare USA ... in moving membership into appropriate case management programs.HealthCare USA ... over 180,000 Medicaid and SCHIP members. Their mission is ...
... hundreds of thousands of people suffering from chronic ... II randomized, double-blind, placebo-controlled trial. Researchers from ... localized (epidural) administration of etanercept, a unique therapeutic ... as a treatment for sciatica. Epidural etanercept for ...
... SILVER SPRING, Md., April 30 Approximately sixty-five state ... will assume primary responsibility for confirmatory testing of Human ... within the next week. Previously, all swine flu specimens ... for final confirmatory testing, which identifies specimens to the ...
... Department of Justice grant creates federal-state-local partnership to ... 30 A sweeping $1.1 million U.S. Justice ... a state prosecution agency to help combat domestic ... grant, the State,s Attorney,s Appellate Prosecutor,s office has ...
... the pancreas, invagination of the pancreas into the small ... according to researchers at the Jefferson Pancreas, Biliary and ... Journal of the American College of Surgeons . ... gold standard for studies. , Removing the head of ...
... announces broad agreement on principles for Getting Health IT ... April 30 Today the Markle Foundation hosts a ... in health information technology (IT) under the American Recovery ... information technology will meet with government and policy experts ...
Cached Medicine News:Health News:SynCare, LLC(TM) Awarded HealthCare USA Health Risk Assessments Contract 2Health News:New Hope for Relief of Chronic Sciatica 2Health News:New Hope for Relief of Chronic Sciatica 3Health News:Public Health Laboratories To Assume Primary Responsibility for Confirmatory Testing of Swine Flu 2Health News:New Illinois Prosecution Unit Helps Protect Women Against Violence 2Health News:Type of connection procedure after pancreatic surgery influenced rate of pancreatic fistula 2Health News:Meaningful Investment of $19 Billion on Health Information Technology 2Health News:Meaningful Investment of $19 Billion on Health Information Technology 3
This popular post op shoe provides quality care at an outstanding value. The semi-rigid outsole provides stability and minimizes flexure....
... Specifically designed for patients who experience severe ... Day prevents tears in fibrous tissue that ... during those first steps in the morning. ... the pain associated with plantar fasciitis and ...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
Resilient insole has a series of removable hexagons for tailored pressure relief....
Medicine Products: